Tesaro Inc (TSRO)

86.09
0.21 0.24
NASDAQ : Health Care
Prev Close 85.88
Open 85.99
Day Low/High 85.47 / 87.38
52 Wk Low/High 29.51 / 99.28
Volume 716.39K
Avg Volume 1.34M
Exchange NASDAQ
Shares Outstanding 51.37M
Market Cap 4.44B
EPS -6.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Here's a Reason Why Tesaro (TSRO) Stock Climbed Today

Here's a Reason Why Tesaro (TSRO) Stock Climbed Today

Tesaro (TSRO) stock closed higher in Monday's trading session after Pfizer (PFE) agreed to pay $14 billion for Medivation (MDVN).

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

Facebook Stands Out and FormFactor Has a Good Start

Facebook Stands Out and FormFactor Has a Good Start

Overall, this is still a good environment for stock picking.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Nice Recovery, But Momentum Is Missing

One bad day does not a market make.

It May Be Dull, but That's No Reason to Be Negative

It May Be Dull, but That's No Reason to Be Negative

Bears continue to have a tough time gaining traction.

In the Red, and Breadth Is Steadily Slipping

In the Red, and Breadth Is Steadily Slipping

There is hesitancy to chase, especially with the FOMC rate decision this afternoon.

Market Momentum Is on the Move

There are still a lot of bulls with a lot of cash.

'Mad Money' Lightning Round: I'm Not Turning My Back on Blackstone

'Mad Money' Lightning Round: I'm Not Turning My Back on Blackstone

Cramer says don't buy Tesaro but do buy Cirrus Logic.

Jim Cramer's 'Mad Money' Recap: Is the Bull Resting or Out the Gate?

Jim Cramer's 'Mad Money' Recap: Is the Bull Resting or Out the Gate?

Cramer says discipline is needed to start trimming positions and taking profits.

I Am Watching Some Momentum Names

I Am Watching Some Momentum Names

Keep in mind that strong action like this tends to create underlying support.

Price Patterns Never Lie

The truth is out there -- in the charts, not reported numbers. 

The Market Mood Is Sour

I am very skeptical that any bounce will last for long.

Summer Trading at Its Finest

There's a transition back to stock-picking as macro matters diminish.

5 Hot Stocks to Watch Right Now

5 Hot Stocks to Watch Right Now

Biotech stocks continue to dominate our top stock charts to watch.

Protect Gains Into the Holiday Weekend

There can be good small-cap trading, but stay selective.

Dr. Marc Siegel Explains Why Tesaro (TSRO) Cancer Drug Is a Big Deal

Dr. Marc Siegel Explains Why Tesaro (TSRO) Cancer Drug Is a Big Deal

In most cases ovarian cancer recurs within two years after chemotherapy, but the Tesaro (TSRO) drug stops that, Dr. Marc Siegel explained on Fox Business today.

Tesaro (TSRO) Stock Slumps on Public Offering, Leerink Lifts Price Target

Tesaro (TSRO) Stock Slumps on Public Offering, Leerink Lifts Price Target

Tesaro (TSRO) stock is falling this morning despite the success of its cancer drug trial after it announced an offering of $300 million worth of common stock to the public.

Analysts' Actions -- General Mills, Priceline, Pulte, Yelp and More

Analysts' Actions -- General Mills, Priceline, Pulte, Yelp and More

Here are Thursday's top research calls, including upgrades for General Mills, Priceline, PulteGroup and Yelp.

What Tesaro's Cancer Drug Success Means for Medivation

What Tesaro's Cancer Drug Success Means for Medivation

Sanofi's $52.50 per share takeout offer for Medivation is looking increasingly unappealing.

Tesaro (TSRO) Stock Skyrockets on Success of Ovarian Cancer Drug

Tesaro (TSRO) Stock Skyrockets on Success of Ovarian Cancer Drug

Tesaro (TSRO) reported positive results of a clinical trial for an ovarian cancer drug.

2 Big-Volume Stocks to Add to Your Buy List -- Plus 5 Risky Ones to Avoid

2 Big-Volume Stocks to Add to Your Buy List -- Plus 5 Risky Ones to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.